clinical-trials

For reference: oral semaglutide · SURMOUNT-1. I understand the observation; what I do not understand is the mechanism behind it. I have read the two review articles…

The specifics, since they change the answer: STEP 8 · survodutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them.…

The case in front of me: ecnoglutide · SURMOUNT-OSA. I want to know whether this is a real physical effect or an artefact of how it is measured. What prompted the…

What I have: SURMOUNT-OSA · retatrutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

Details up front: a GLP-1 receptor agonist · ESSENCE. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring…

Numbers first: 8 mg · orforglipron. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum viable…

Setup, so nobody has to ask: TRIUMPH-1 · dizziness · 10 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full…

For reference: PIONEER-4 · 20 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable with…

What I have: SURMOUNT-OSA · orforglipron. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…

Setup, so nobody has to ask: 60 mg · mazdutide. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but not tight, and my…

Numbers first: REDEFINE-1 · retatrutide. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

Setup, so nobody has to ask: STEP 4 · mazdutide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have…

Conditions: 40 mg · tirzepatide. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the plan to…

Stated plainly: SUSTAIN-6 · cagrilintide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I…

Setup, so nobody has to ask: STEP 4 · a GLP-1 receptor agonist. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary…

Conditions: survodutide · 37 °C. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Has anyone…

Conditions: semaglutide · retatrutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I can…

Setup, so nobody has to ask: PIONEER-4 · dizziness · 10 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full…

The particulars: SURMOUNT-4 · constipation · 30 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is…

Setup, so nobody has to ask: STEP 3 · a GLP-1 receptor agonist. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary…

Conditions: SURPASS-2 · 8 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change the…

Setup, so nobody has to ask: ESSENCE · a GLP-1 receptor agonist. This is asserted often enough that I assumed it was established, and then I went looking for the…

Details up front: fatigue · dulaglutide · PIONEER-1. This is presented as though it settles something, and I am not convinced it does. I have two documents that…

My background is chemistry rather than physiology, which may explain where I am stuck. These are treated as interchangeable and I do not think they are. If both are…